Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Genetics,Oncology
Link
http://link.springer.com/content/pdf/10.1186/s12885-016-2159-7
Reference55 articles.
1. Casali PG. Rare cancers: work in progress in Europe. Ann Oncol. 2014;25(4):914.
2. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer. 2011;47(17):2493–511.
3. RARE CANCERS EUROPE. http://www.rarecancerseurope.org/ . Accessed 14 Feb 2016.
4. Casali PG, Bruzzi P, Bogaerts J, Blay JY, Rare Cancers Europe Consensus P. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol. 2015;26(2):300–6.
5. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44(1):123–30.
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis;Recent Patents on Anti-Cancer Drug Discovery;2023-11
2. Survival nomogram for patients with thymic squamous cell carcinoma, based on the SEER database and an external validation cohort;Discover Oncology;2023-06-20
3. Salvage Chemotherapy in Patients with Previously Treated Thymic Carcinoma;Cancers;2021-10-29
4. Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma;Cancer Medicine;2020-08-19
5. Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study;The Oncologist;2019-11-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3